CD147 in Ovarian and Other Cancers

Yang, Hong; Chen, Biliang

doi:10.1097/igc.0b013e3182749139

Cited by 24 publications

(19 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD147/EMMPRIN is a glycosylated, multifunctional molecule that participates in tumor progression 61 . In the present study, we quantitatively analyzed the data from 53 studies, including 68 datasets, to examine the associations between CD147/EMMPRIN expression and its prognosis predictive value in cancer.…”

Section: Discussionmentioning

confidence: 99%

CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

Xin

Zeng

et al. 2016

Sci Rep

109

View full text Add to dashboard Cite

CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

Xin

Zeng

et al. 2016

Sci Rep

109

View full text Add to dashboard Cite

show abstract

“…Molecular factors not included in our array, such as gp100, ERCC, CD44, CD147, c-met, IL-6, ALDH, CD117 and BMP2 have also been studied in the context of chemoresistance in ovarian cancer. [ 48 – 51 ]. Although these molecules represent potentially interesting therapeutic targets, at the moment these results have been contradictive and not prospectively validated in large patient cohorts.…”

Section: Discussionmentioning

confidence: 99%

The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling

et al. 2016

View full text Add to dashboard Cite

Advanced ovarian cancer (AOC) is one of the leading lethal gynecological cancers in developed countries. Based on the important role of angiogenesis in ovarian cancer oncogenesis and expansion, we hypothesized that the development of an “angiogenic signature” might be helpful in prediction of prognosis and efficacy of anti-angiogenic therapies in this disease. Sixty-nine samples of ascitic fluid- 35 from platinum sensitive and 34 from platinum resistant patients managed with cytoreductive surgery and 1st-line carboplatin-based chemotherapy- were analyzed using the Proteome ProfilerTM Human Angiogenesis Array Kit, screening for the presence of 55 soluble angiogenesis-related factors. A protein profile based on the expression of a subset of 25 factors could accurately separate resistant from sensitive patients with a success rate of approximately 90%. The protein profile corresponding to the “sensitive” subset was associated with significantly longer PFS (8 [95% Confidence Interval {CI}: 8–9] vs. 20 months [95% CI: 15–28]; Hazard ratio {HR}: 8.3, p<0.001) and OS (20.5 months [95% CI: 13.5–30] vs. 74 months [95% CI: 36-not reached]; HR: 5.6 [95% CI: 2.8–11.2]; p<0.001). This prognostic performance was superior to that of stage, histology and residual disease after cytoreductive surgery and the levels of vascular endothelial growth factor (VEGF) in ascites. In conclusion, we developed an “angiogenic signature” for patients with AOC, which can be used, after appropriate validation, as a prognostic marker and a tool for selection for anti-angiogenic therapies.

show abstract

“…13 Other functions of CD147 include inducing angiogenesis, regulating metabolism, and conferring resistance to chemotherapeutic drugs. 14 The overexpression of CD147 in cancer tissues is correlated with poor prognosis of patients with several types of solid tumors, including esophageal cancer. 15,16 These suggest that the effects of a CD147 targeting agent may result in inhibition of tumor proliferation, invasion, and metastasis.…”

Section: Introductionmentioning

confidence: 99%

Dual effects of an anti-CD147 antibody for Esophageal cancer therapy

Wang

Zhang

Sun³

et al. 2019

Cancer Biology & Therapy

View full text Add to dashboard Cite

Background: Esophageal cancer is a highly aggressive neoplasm. Targeted therapy has been proven to be a promising way for cancer therapy. Here, we report a novel anti-CD147 antibody for esophageal cancer therapy, which is a chimeric antibody with modified glycoform in Fc region. Methods: ADCC assay was used to explore the antitumor efficacy of Metuzumab against esophageal cancer in vitro. Wound healing assay and Boyden Chamber invasion assay were performed to explore whether Metuzumab could inhibit migration and invasion of esophageal cancer in vitro. Insulin-like growth factors 1 (IGF-1) and PI3k/Akt was assayed for elaborating antagonistic mechanism of Metuzumab in migration and invasion of esophageal cancer cells. Subcutaneous xenograft nude mouse model was used to investigate the antitumor efficacy of Metuzumab against esophageal cancer in vivo. The esophageal cancer tissue microarrays (TMA) was examined for identification of association of CD147 with lymph node metastasis, and the footpad xenograft nude mouse model was used to explore whether Metuzumab could inhibit lymph node metastasis of esophageal cancer in vivo. Results: The results showed that Metuzumab exhibited higher ADCC compared to the wild type antibody cHAb18. Metuzumab inhibited migration and invasion of esophageal cancer through blockade of CD147 in vitro. The results of Western blot showed Metuzumab might inhibit migration and invasion of esophageal cancer cells through suppressing activation of PI3k/Akt and expression of IGF-1. Experiments in vivo showed that Metuzumab exhibited significant antitumor efficacy and inhibited lymph node metastasis of esophageal cancer in xenograft models. The immunochemical staining of TMA showed CD147 was high-expressed on various kinds of esophageal cancer tissues and associated with the grade of lymph node-metastasis. Conclusions: The in vitro and in vivo study demonstrated dual effects of Metuzumab in effectively mediating ADCC by activating effector cells, and inhibiting metastasis of esophageal cancer through blockade the function of CD147, providing justification for moving Metuzumab forward to clinical development in esophageal cancer.

show abstract

CD147 in Ovarian and Other Cancers

Cited by 24 publications

References 63 publications

CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling

Dual effects of an anti-CD147 antibody for Esophageal cancer therapy

Contact Info

Product

Resources

About